stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Inventiva S.A.

France · NASDAQ: IVA · Market cap: · P/E: · P/S:

Inventiva is a biotech company that develops oral pill medicines for liver disease and rare genetic disorders.

Inventiva is a small French biotech company that designs pills — not injections, not infusions — to treat a serious liver disease called MASH and a handful of rare diseases. Its medicines are small molecules, meaning they are simple chemical compounds that can be swallowed and absorbed by the body, which matters a lot for patients who might otherwise face regular injections or invasive procedures.

Its lead program is lanifibranor, an experimental pill for MASH, a fatty liver disease that can progress to scarring, cirrhosis, and liver failure. MASH is a huge, underserved market with few approved drugs, and that is exactly why Inventiva is interesting to investors — it is a bet on a single high-risk, high-reward asset. The company also runs a portfolio of earlier-stage programs aimed at rare genetic conditions like mucopolysaccharidosis, where the biology of its compounds may offer a new way to treat patients with few options. Because it is a clinical-stage biotech, Inventiva does not yet sell its main drug and does not make meaningful product revenue. Its money comes from research collaborations and licensing deals with larger partners, and it funds its work by raising capital from investors. That means the business lives or dies on clinical trial results and regulatory decisions; a good trial readout can send the stock soaring, and a bad one can crush it.


The company is based in Daix, France, near Dijon, and it also trades on Euronext Paris. Its path has not been smooth: it has had to raise cash repeatedly to keep its trials going, and it has faced setbacks and restructuring along the way. The core story is simple — Inventiva is a science-heavy, cash-hungry company trying to turn one promising pill for a widespread liver disease into an approved medicine, and everything else in the business revolves around that gamble.

Saved answer · last researched 15 Nov 2026